<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17941" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Atheroembolic Kidney Disease</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vaidya</surname>
            <given-names>Prabhakar N.</given-names>
          </name>
          <aff>Campbell University School of OM</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hashmi</surname>
            <given-names>Muhammad F.</given-names>
          </name>
          <aff>National Health Service</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Finnigan</surname>
            <given-names>Nancy A.</given-names>
          </name>
          <aff>Campbell University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Prabhakar Vaidya declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Hashmi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nancy Finnigan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>6</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17941.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Atheroembolic renal disease (AERD), also known as cholesterol atheroembolic renal disease or cholesterol embolism, is a serious condition characterized by the sudden occlusion of small renal arteries by cholesterol crystals that originate from ruptured atherosclerotic plaques elsewhere in the body, typically in large arteries such as the aorta. These cholesterol emboli can dislodge and travel through the bloodstream until they become lodged in the smaller arteries of the kidneys, causing obstruction and subsequent damage. The condition often presents as acute kidney injury, with symptoms ranging from mild impairment to severe renal failure. Patients may experience nonspecific symptoms such as flank pain, hypertension, acute decline in kidney function, or signs of systemic inflammation like eosinophilia. Diagnosis of AERD can be challenging due to its variable presentation and the need to exclude other causes of renal impairment. Imaging studies such as Doppler ultrasound or angiography may reveal characteristic findings such as a "string of beads" appearance due to arterial wall damage from emboli.</p>
        <p>Participants in this activity gain a deeper understanding of the condition's pathophysiology, clinical presentation, and diagnostic challenges. They acquire knowledge on how cholesterol emboli from atherosclerotic plaques can lead to renal artery occlusion and subsequent acute kidney injury. Learners also grasp the importance of clinical suspicion in cases presenting with nonspecific symptoms, prompting consideration of AERD as a differential diagnosis. Moreover, participants in the activity enhance their skills in interdisciplinary collaboration, recognizing the pivotal role of various healthcare professionals&#x02014;such as physicians, nurses, pharmacists, and public health experts&#x02014;in optimizing patient outcomes. Collaborative efforts enable comprehensive patient assessment, timely diagnostic interventions (such as imaging studies), and the implementation of multifaceted management strategies aimed at preventing further embolic events and preserving renal function. &#x000a0;</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Implement evidence-based management strategies to mitigate the risk of cholesterol emboli dislodgment and subsequent renal damage in those with&#x000a0;atheroembolic renal disease.</p></list-item><list-item><p>Implement preventive strategies to reduce the risk of atheroembolic renal disease&#x000a0;in patients undergoing invasive procedures.</p></list-item><list-item><p>Assess the extent of renal impairment in patients suspected of having atheroembolic renal disease&#x000a0;using appropriate diagnostic tools.</p></list-item><list-item><p>Collaborate with multidisciplinary teams to develop comprehensive care plans for patients with or at risk of atheroembolic renal disease.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17941&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17941">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17941.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Atheroembolic renal disease (AERD), also known as cholesterol atheroembolic renal disease, atheroembolism, cholesterol embolism,&#x000a0;or cholesterol crystal embolization,&#x000a0;is often an underdiagnosed clinical illness.<xref ref-type="bibr" rid="article-17941.r1">[1]</xref><xref ref-type="bibr" rid="article-17941.r2">[2]</xref><xref ref-type="bibr" rid="article-17941.r3">[3]</xref>&#x000a0;AERD is often a diagnosis of exclusion as definitive findings are rare, and clinical history often overlaps with many other conditions. However, the incidence is increasing with the increasing use of catheter-based treatment approaches and increased prevalence of risk factors. A clinical triad of an inciting event, acute or subacute renal injury, and skin findings should raise suspicion for AERD.<xref ref-type="bibr" rid="article-17941.r4">[4]</xref><xref ref-type="bibr" rid="article-17941.r5">[5]</xref></p>
        <p>Cholesterol emboli are an important cause of renal impairment. Irregularly shaped atheroemboli can cause partial or complete obstruction of small renal vessels, resulting in ischemia. A vasculitis-like picture is commonly seen with an inflammatory reaction and, ultimately, giant cell formation.<xref ref-type="bibr" rid="article-17941.r6">[6]</xref> The relation of these emboli may be temporally found to the use of anticoagulants, vascular&#x000a0;manipulation, or thrombolytic drug use.<xref ref-type="bibr" rid="article-17941.r7">[7]</xref> However, spontaneous cases have also been reported. Patients&#x000a0;who develop atheroembolic renal disease&#x000a0;may present with a spectrum of clinical presentations of acute renal failure ranging from mild or asymptomatic to life-threatening conditions.</p>
        <p>Atheroembolic renal disease is caused by the occlusion of the small renal arteries by cholesterol crystal emboli from ulcerated atherosclerotic plaques and is a part of systemic atheroembolism disease.<xref ref-type="bibr" rid="article-17941.r8">[8]</xref><xref ref-type="bibr" rid="article-17941.r9">[9]</xref>&#x000a0;The proximity of the kidneys to the abdominal aorta and high renal blood flow makes them a frequent target of cholesterol emboli. Results from one autopsy study revealed that 74% of cases with cholesterol atheroembolic disease involved the kidneys.<xref ref-type="bibr" rid="article-17941.r6">[6]</xref></p>
      </sec>
      <sec id="article-17941.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Atheroembolic renal disease occurs in patients with atherosclerotic vascular disease, and typically, these patients have significant atherosclerotic plaques in the aorta and large-to-medium-sized vessels. These plaques have a lipid-rich core and a thin fibrous cap. Mechanical and hemodynamic stresses can rupture the fibrous cap and release the underlying extracellular cholesterol-rich matrix, which enters circulation and eventually lodges at a distal site, causing vascular occlusion.<xref ref-type="bibr" rid="article-17941.r10">[10]</xref></p>
        <p>Frequently an iatrogenic disease, AERD may follow surgical procedures like coronary artery bypass grafting, coronary stenting, abdominal aortic aneurysm repair, angiography, angioplasty, or endovascular grafting. In a small number of patients, atheroembolic renal disease may occur spontaneously without any inciting or triggering factors.<xref ref-type="bibr" rid="article-17941.r11">[11]</xref><xref ref-type="bibr" rid="article-17941.r12">[12]</xref><xref ref-type="bibr" rid="article-17941.r13">[13]</xref>&#x000a0;The release of cholesterol&#x000a0;emboli into the circulation may occur spontaneously, post-intravascular trauma caused by angiographic catheters, or due to the use of anticoagulants and thrombolytics. Like the native kidneys, atheroembolic renal disease can also affect a transplanted kidney&#x000a0;and must be considered&#x000a0;when diagnosing a patient with worsening renal allograft function.<xref ref-type="bibr" rid="article-17941.r14">[14]</xref><xref ref-type="bibr" rid="article-17941.r15">[15]</xref><xref ref-type="bibr" rid="article-17941.r16">[16]</xref></p>
        <p>The most common cause of AERD is coronary angiography with an estimated incidence of 0.06% to 1.8%. This condition can also result from hemodynamic stress, reported in up to 30% of cases.<xref ref-type="bibr" rid="article-17941.r4">[4]</xref>&#x000a0;A transbrachial artery approach may cause fewer renal emboli than a transfemoral, but this has not been definitively proven.<xref ref-type="bibr" rid="article-17941.r17">[17]</xref>&#x000a0;Cholesterol emboli can cause damage to other organs in the vascular territory of the embolic source. Extra-renal manifestations can include pancreatitis, gastric ulcers, and intestinal ischemia.<xref ref-type="bibr" rid="article-17941.r18">[18]</xref></p>
        <p>There are 3 forms of atheroembolic renal disease:</p>
        <list list-type="order">
          <list-item>
            <p>An acute form&#x000a0;that develops a few days after the inciting event and is due to a massive embolization.</p>
          </list-item>
          <list-item>
            <p>The second type of AERD develops subacutely or in a stepwise fashion, probably due to recurrent embolization or endothelial inflammation that follows an initial ischemic insult and which results in further vessel occlusion. This is the most frequently observed form of AERD.</p>
          </list-item>
          <list-item>
            <p>A third variety presents as chronic and slowly progressive impairment of renal function and is often mistaken for nephrosclerosis or ischemic nephropathy.<xref ref-type="bibr" rid="article-17941.r19">[19]</xref><xref ref-type="bibr" rid="article-17941.r20">[20]</xref><xref ref-type="bibr" rid="article-17941.r21">[21]</xref></p>
          </list-item>
        </list>
        <p>In the first type involving massive embolization, a rise in creatinine will be immediate. On the other hand, with subacute or chronic embolization, the rise in creatinine may occur days or weeks after the initial insult.<xref ref-type="bibr" rid="article-17941.r22">[22]</xref></p>
      </sec>
      <sec id="article-17941.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Atheroembolic renal disease occurs in patients with systemic generalized atherosclerosis. Risk factors include older age, male sex, diabetes, hypertension, hyperlipidemia, and smoking. These patients frequently have coronary artery disease, cerebrovascular disease, renal artery stenosis, renal insufficiency, aortic aneurysm, or other similar atherosclerotic diseases.<xref ref-type="bibr" rid="article-17941.r8">[8]</xref><xref ref-type="bibr" rid="article-17941.r22">[22]</xref></p>
        <p>The reported incidence ranges between 1% and 5% based on different study protocols and criteria used for diagnosis.<xref ref-type="bibr" rid="article-17941.r9">[9]</xref><xref ref-type="bibr" rid="article-17941.r11">[11]</xref><xref ref-type="bibr" rid="article-17941.r13">[13]</xref><xref ref-type="bibr" rid="article-17941.r18">[18]</xref>&#x000a0;In older adults with atherosclerosis, atheroembolic renal disease is being increasingly seen. Results from a study found that 60% of patients with atheroembolic renal disease were older than 70.<xref ref-type="bibr" rid="article-17941.r19">[19]</xref>&#x000a0;The exact&#x000a0;prevalence of&#x000a0;atheroembolic renal disease is unknown; AERD is likely an underdiagnosed condition.<xref ref-type="bibr" rid="article-17941.r8">[8]</xref>&#x000a0;Clinical data is&#x000a0;based on isolated case reports, case series, and clinicopathologic case discussions.</p>
      </sec>
      <sec id="article-17941.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>During surgical procedures, mechanical trauma (incision, clamping, or manipulation of the vessel) may disrupt the atherosclerotic plaques. During angiography or angioplasty, catheter manipulations disrupt the plaques, exposing the soft, cholesterol-laden core of the plaque to the arterial circulation. Anticoagulants and thrombolytic therapy prevent the formation of a protective thrombus overlying an ulcerated plaque and can also initiate disruption of a plaque by causing hemorrhage into it, therefore exposing plaques to the hemodynamic stress of circulating blood.<xref ref-type="bibr" rid="article-17941.r13">[13]</xref> Once in circulation, cholesterol crystal emboli lodge in small arteries, 150 mm to 200 mm in diameter. These emboli cause partial occlusion of the vessel and distal ischemia, and this is followed by an inflammatory reaction, intimal proliferation, and intravascular fibrosis. The entire process results in further obliteration of the lumen and more ischemic changes.<xref ref-type="bibr" rid="article-17941.r6">[6]</xref></p>
        <p>The exact mechanism underlying atheroembolic renal disease is not fully known. The local tissue necrosis and inflammatory&#x000a0;response invoked by cholesterol crystals&#x000a0;play a significant role. Furthermore, the renin-angiotensin-aldosterone system and&#x000a0;complement activation also contribute to the development of atheroembolic renal disease.</p>
        <p>
<bold>Necroinflammation</bold>
</p>
        <p>Cholesterol crystals cause tissue damage directly by a mechanical obstruction, leading to vessel obstruction, tissue ischemia, and cell necrosis, which is referred to as &#x0201c;necroinflammation.&#x0201d;<xref ref-type="bibr" rid="article-17941.r23">[23]</xref>&#x000a0;The local inflammatory&#x000a0;cascade initiated by cholesterol crystals plays a crucial part in luminal occlusion and consequent renal insufficiency. The cholesterol crystals set off a foreign-body inflammatory response around the arterioles, causing infiltration of the macrophages and a giant cell reaction.</p>
        <p>Cholesterol crystals appear as an endogenous instigator of inflammation. Results from one study reported that cholesterol crystals induce activation of interleukin (IL)-1&#x003b2; in mononuclear phagocytes via the nucleotide-binding and oligomerization domain (NOD)-like receptor protein 3 (NLRP3) inflammasome.<xref ref-type="bibr" rid="article-17941.r24">[24]</xref>&#x000a0;This inflammasome is an intracellular platform for the translation of several danger signals into the activation of caspase-1 and the release of interleukin-1&#x003b2;. The NLRP3 inflammasome activates the macrophages to secrete mature IL-1&#x003b2; and &#x003b1;,&#x000a0;causing cell necrosis.<xref ref-type="bibr" rid="article-17941.r25">[25]</xref> Additionally, the cholesterol emboli induce the production of IL-&#x003b1;/&#x003b2; via the activation of PI3K and&#x000a0;Syk in macrophages and dendritic cells.<xref ref-type="bibr" rid="article-17941.r26">[26]</xref>&#x000a0;Moreover, the atheroemboli directly adhere to the human macrophage-inducible C-type lectin, releasing pro-inflammatory cytokines, such as macrophage inflammatory protein 2 (MIP-2) and tumor necrosis factor (TNF).<xref ref-type="bibr" rid="article-17941.r27">[27]</xref><xref ref-type="bibr" rid="article-17941.r6">[6]</xref><xref ref-type="bibr" rid="article-17941.r27">[27]</xref></p>
        <p>
<bold>Activation of the Renin-Angiotensin-Aldosterone System&#x000a0;</bold>
</p>
        <p>Blood pressure in patients with&#x000a0;AERD can be difficult to control, as it activates the renin-angiotensin-aldosterone system. Obstruction of the renal vasculature by cholesterol crystals reduces focal blood perfusion and increases oxidative stress. This, in turn, leads to apoptosis, inflammation, and fibrosis.[<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485944/#B25-ijms-18-01120">25</ext-link>]</p>
        <p>
<bold>Complement Activation</bold>
</p>
        <p>Complement activation is associated with the inflammatory response secondary to atherosclerosis. Cholesterol crystals&#x000a0;trigger both the classical and alternative complement pathways.<xref ref-type="bibr" rid="article-17941.r28">[28]</xref><xref ref-type="bibr" rid="article-17941.r29">[29]</xref>&#x000a0;Emboli can activate the classical complement cascade and cause TNF release, which leads to endothelial activation in vitro.<xref ref-type="bibr" rid="article-17941.r30">[30]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-17941.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>In the kidney, emboli typically lodge in the arcuate and interlobar arteries and are seen on light microscopy as elongated biconvex transparent needle-shaped clefts. These clefts represent the cholesterol crystals that are dissolved during tissue processing and are sometimes called "ghost cells".<xref ref-type="bibr" rid="article-17941.r22">[22]</xref>&#x000a0;Endothelial inflammatory response ensues and eventually leads to complete obliteration of blood flow within weeks or months.<xref ref-type="bibr" rid="article-17941.r31">[31]</xref>&#x000a0;Distal to the occlusion, inflammatory and necrotic changes may be present.<xref ref-type="bibr" rid="article-17941.r22">[22]</xref>&#x000a0;Glomeruli may appear normal in the initial stages, but eventually, there may be glomerular collapse or shrinkage. Other changes in histology may include acute tubular necrosis, interstitial fibrosis, and tubular atrophy.<xref ref-type="bibr" rid="article-17941.r31">[31]</xref>&#x000a0;Please see <bold>Images.</bold> Cholesterol Emboli in Glomerulus.</p>
      </sec>
      <sec id="article-17941.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Atheroembolic renal disease is usually part of generalized atheroembolic disease, and the most commonly affected sites are the skin, lower extremity skeletal muscles, gastrointestinal tract, kidneys, and brain. Constitutional symptoms may include fever, weight loss, fatigue, or anorexia. Clinical manifestations include livedo reticularis, blue toe/purple toe syndrome, abdominal pain, and neurological deficits. Neurologic deficits may include amaurosis fugax, tia, stroke, headache, mental status changes, neuropathy, or spinal cord infarction.<xref ref-type="bibr" rid="article-17941.r6">[6]</xref>&#x000a0;AERD presents with acute/subacute/chronic renal failure, mild-to-moderate proteinuria, hematuria, accelerated hypertension, or new onset hypertension.<xref ref-type="bibr" rid="article-17941.r4">[4]</xref><xref ref-type="bibr" rid="article-17941.r8">[8]</xref><xref ref-type="bibr" rid="article-17941.r32">[32]</xref>&#x000a0;</p>
        <p>If the embolic source is the ascending aorta (although a descending aortic source would be more common), Hollenhorst plaques may be visualized on the retina. See StatPearls' companion review, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/22965">Hollenhorst Plaque</ext-link>," for further review and imagery. Skin findings suggestive of cholesterol emboli include livedo reticularis, blue toe syndrome (painful bluish/purple discoloration), and purpura, although these findings can also be seen with vasculitis.<xref ref-type="bibr" rid="article-17941.r22">[22]</xref><xref ref-type="bibr" rid="article-17941.r33">[33]</xref>&#x000a0;Changes associated with these emboli may include edema.<xref ref-type="bibr" rid="article-17941.r34">[34]</xref></p>
        <p>The most common extra-renal manifestation is in the skin, with abnormalities noted in 75% to 96% of known cholesterol emboli cases. Extra-renal manifestations are possible, especially in the gastrointestinal territory, given the proximity of its vascular territory. If this is the case, manifestations such as abdominal pain, nausea, or vomiting may occur. Pancreatic infarcts can cause pancreatitis and its associated symptoms.<xref ref-type="bibr" rid="article-17941.r6">[6]</xref><xref ref-type="bibr" rid="article-17941.r18">[18]</xref>&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-17941.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The combination of risk factors, inciting or triggering events, acute/subacute renal failure, and signs of peripheral emboli suggest an AERD diagnosis. If these are present, the diagnosis of AERD can be made without a kidney biopsy. Renal biopsy, however, may be required in some cases to exclude processes like vasculitis, acute tubular necrosis, and allergic interstitial nephritis and may provide a definite diagnosis.</p>
        <p>If there are skin lesions (digital infarcts, livedo reticularis), a skin biopsy may be a simple and minimally invasive way to diagnose the condition. If muscle damage is present and a specific muscle can be identified, a muscle biopsy may be another minimally invasive way to establish the diagnosis.<xref ref-type="bibr" rid="article-17941.r18">[18]</xref>&#x000a0;One laboratory finding suggestive of AERD is eosinophilia (present in about 80% of cases), but this may be a transitory sign.<xref ref-type="bibr" rid="article-17941.r22">[22]</xref>&#x000a0;Eosinophiluria, elevated C-reactive peptide, and hypocomplementemia may also occur, but these are not sensitive nor specific to AERD.<xref ref-type="bibr" rid="article-17941.r6">[6]</xref><xref ref-type="bibr" rid="article-17941.r8">[8]</xref><xref ref-type="bibr" rid="article-17941.r32">[32]</xref></p>
      </sec>
      <sec id="article-17941.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>There is no specific therapy for atheroembolic renal disease and treatment is mostly symptomatic and supportive. Anticoagulation should be discontinued, and the performance of more invasive diagnostic/therapeutic vascular procedures or surgery should be avoided or delayed, if possible. Treatment with aspirin and statins, smoking cessation, blood pressure control, and glycemic control are part of atherosclerosis management. Distal protection vascular devices are being used in interventional procedures to prevent embolic material from lodging in distal sites.<xref ref-type="bibr" rid="article-17941.r8">[8]</xref>&#x000a0;</p>
        <p>The aim of treatment is to&#x000a0;slow or halt&#x000a0;the progression of ischemia of the tissues and further showering of cholesterol crystals. Avoiding nephrotoxins and limiting contrast exposure can also help decrease the incidence of AERD. Animal studies have also shown that hyperglycemia and hyperuricemia worsen cholesterol emboli-associated renal disease through different mechanisms. Renal replacement therapy may be required for supportive management if renal function does not improve.<xref ref-type="bibr" rid="article-17941.r5">[5]</xref><xref ref-type="bibr" rid="article-17941.r35">[35]</xref></p>
        <p>
<bold>Corticosteroids</bold>
</p>
        <p>The&#x000a0;purpose of corticosteroid use is to decrease the inflammatory response to atheroembolization. However, the effects of steroids remain controversial. Some studies demonstrate that the administration of oral prednisolone at a dose of 1 mg/kg/day results in overall clinical improvement and better renal outcomes.<xref ref-type="bibr" rid="article-17941.r36">[36]</xref>&#x000a0;However, other studies&#x000a0;reveal that steroids do not have a significant long-term effect on renal outcomes and may even result in an increased risk of mortality.<xref ref-type="bibr" rid="article-17941.r37">[37]</xref></p>
        <p>
<bold>Lipid-lowering Therapies</bold>
</p>
        <p>Statins may have a&#x000a0;positive effect on AERD by contributing to the stabilization of plaque and its regression through their anti-inflammatory and&#x000a0;lipid-lowering properties.<xref ref-type="bibr" rid="article-17941.r38">[38]</xref></p>
        <p>
<bold>Dialysis and Other Therapies</bold>
</p>
        <p>Patients with acute kidney injury may need renal replacement therapy. Both peritoneal dialysis and hemodialysis are useful means of treating renal failure in such patients.</p>
      </sec>
      <sec id="article-17941.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Several other entities can have similar clinical presentations.</p>
        <list list-type="bullet">
          <list-item>
            <p>In contrast nephropathy, an increase in serum creatinine starts a day or two after exposure to contrast. The serum creatinine peaks in approximately one week and returns to baseline within 10 to 14 days. On the other hand, AERD frequently has a delayed onset, usually days to weeks, and a protracted course. The outcome is often poor, resulting in progressive renal failure requiring dialysis.<xref ref-type="bibr" rid="article-17941.r32">[32]</xref></p>
          </list-item>
          <list-item>
            <p>Systemic vasculitis is another consideration since there is multisystem involvement and complement levels can be decreased in both atheroembolic renal disease and systemic vasculitis. Serological testing, biopsy of the affected organ, or angiography may be needed to rule out this disease, since the management and outcomes of vasculitis are very different.</p>
          </list-item>
          <list-item>
            <p>Subacute bacterial endocarditis may also enter into differential diagnosis due to multisystem manifestations and low complement levels.</p>
          </list-item>
          <list-item>
            <p>Rising serum creatinine, mild-to-moderate proteinuria, hematuria, and eosinophilia may also raise the possibility of acute interstitial nephritis.<xref ref-type="bibr" rid="article-17941.r9">[9]</xref><xref ref-type="bibr" rid="article-17941.r31">[31]</xref></p>
          </list-item>
          <list-item>
            <p>Chronic forms of atheroembolic renal disease may be mistaken for hypertensive nephrosclerosis or ischemic nephropathy if peripheral manifestations are subtle or missed. Renal biopsy may be crucial in these cases to make the diagnosis.<xref ref-type="bibr" rid="article-17941.r6">[6]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17941.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>AERD is often associated with irreversible organ damage&#x000a0;with a poor prognosis. The renal outcome&#x000a0;varies, with some patients requiring maintenance dialysis and others improving but with a variable degree of residual chronic renal impairment. Renal function may improve in approximately one-third of these patients after variable time without further embolic events.<xref ref-type="bibr" rid="article-17941.r8">[8]</xref><xref ref-type="bibr" rid="article-17941.r9">[9]</xref>&#x000a0;Some study results show that patients with AERD have the potential to recover renal function after a longer dialysis-dependent time than other etiologies of end-stage renal disease.<xref ref-type="bibr" rid="article-17941.r13">[13]</xref></p>
        <p>Around 30% to 55% of cases of acute/subacute&#x000a0;AERD need&#x000a0;renal replacement therapy. Improvement in renal function has been observed in only 21% to 28% of these patients.<xref ref-type="bibr" rid="article-17941.r39">[39]</xref><xref ref-type="bibr" rid="article-17941.r40">[40]</xref>&#x000a0;One- and 2-year survival rates of 87% and 75%, respectively, have been reported. However, mortality is linked more to the causes of AERD than the renal disease itself.<xref ref-type="bibr" rid="article-17941.r13">[13]</xref><xref ref-type="bibr" rid="article-17941.r41">[41]</xref>&#x000a0;The&#x000a0;most common cause of mortality is cardiovascular disease.<xref ref-type="bibr" rid="article-17941.r42">[42]</xref></p>
      </sec>
      <sec id="article-17941.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Atheroembolic disease can lead to the following complications of which providers should be aware:</p>
        <list list-type="bullet">
          <list-item>
            <p>Irreversible organ damage</p>
          </list-item>
          <list-item>
            <p>End-stage renal disease</p>
          </list-item>
          <list-item>
            <p>Visceral ischemia</p>
          </list-item>
          <list-item>
            <p>Membranous nephropathy</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17941.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Prevention is&#x000a0;critical for&#x000a0;atheroembolic renal disease, as no effective treatment is available at present. Acting in anticipation and initiating prophylaxis against further atheroembolization is useful. As it is a serious complication of many invasive vascular procedures, excess anticoagulation, surgical procedures, and angiography should be limited as much as possible, particularly in cases of known atherosclerosis. Newer noninvasive diagnostic investigations, such as spiral computed tomography, angiography, duplex ultrasonography, and geomagnetic resonance, may reduce iatrogenic AERD.&#x000a0;Patients should be made aware of their disease and its implications for different body systems. If renal replacement is indicated, a thorough education program on the different modalities and renal transplant options, if applicable, should be implemented.</p>
      </sec>
      <sec id="article-17941.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Pearls and other vital information on AERD include:</p>
        <list list-type="bullet">
          <list-item>
            <p>ARED is caused by the occlusion of the small renal arteries by cholesterol crystal emboli from ulcerated atherosclerotic plaques and is a part of systemic atheroembolism disease.</p>
          </list-item>
          <list-item>
            <p>AERD of often missed or misdiagnosed due to non-specific presentations and overlapping risk factors with other common renal diseases.</p>
          </list-item>
          <list-item>
            <p>A clinical triad of an inciting event, acute or subacute renal injury, and skin findings should raise suspicion for AERD.</p>
          </list-item>
          <list-item>
            <p>Common extrarenal manifestations include skin findings such as livedo reticularis, blue of purple toe syndrome, and less commonly, purpura.</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal manifestations are also common and can include abdominal pain, ulcers, or pancreatitis.</p>
          </list-item>
          <list-item>
            <p>Laboratory findings may include eosinophilia, eosinophiluria, low complement levels, and elevated C-reactive protein. However, these findings are neither specific nor sensitive.</p>
          </list-item>
          <list-item>
            <p>No specific treatment exists for AERD other than mitigating risk factors such as hypertension, hyperlipidemia, hyperglycemia, and hyperuricemia.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17941.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Restricting the use of angiography and interventional or surgical vascular procedures in those with a high risk of atheroembolic events is imperative for the primary prevention of this disease. The use of alternate diagnostic procedures like magnetic resonance angiography or computer-assisted topographic angiography should be considered in those who have a higher risk if the alternate procedure can provide adequate information. Minimizing direct trauma of the tip of the catheter to the atheromatous wall of the vessel may also reduce the risk of atheroembolization. Further, using embolic protection devices during vascular procedures may catch the atheromatous debris and prevent migration to distal sites, thereby reducing the risk of embolization. Interprofessional coordination among surgical providers, primary care providers, nephrologists, and radiologists is key to mitigating adverse outcomes. Nurses are crucial in relaying a patient's daily clinical status to appropriate providers, pharmacists help educate patients and avoid nephrotoxins, and social workers help coordinate discharge planning and appropriate follow-up care.&#x000a0;</p>
        <p>A strategic approach is equally crucial, involving&#x000a0;strategies to optimize treatment plans and minimize&#x000a0;adverse effects. Ethical considerations must guide decision-making, ensuring informed consent and respecting patient autonomy in treatment choices and awareness of possible complications. Each healthcare professional must be aware of their responsibilities and contribute their unique expertise to the patient's care plan, fostering a multidisciplinary approach. Effective interprofessional communication is paramount, allowing seamless information exchange and collaborative decision-making among the team members. Care coordination plays a pivotal role in ensuring that the patient's journey from diagnosis to treatment and follow-up is well-managed, minimizing errors and enhancing patient safety. By embracing these principles of skill, strategy, ethics, responsibilities, interprofessional communication, and care coordination, healthcare professionals can deliver patient-centered care, ultimately improving patient outcomes and enhancing team performance in the management of renal atheroembolic disease.</p>
      </sec>
      <sec id="article-17941.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17941&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17941">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/kidney-health/atheroembolic-kidney-disease/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=17941">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17941/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17941">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-17941.s17">
        <fig id="article-17941.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Cholesterol Emboli in the Glomerulus, Histology, H&#x00026;E. Artery showing atheroembolus with cholesterol clefts embedded within prominent intimal fibrosis (arrow), hematoxylin &#x00026; eosin stain. Seker P. Kidney biopsy of the month: atheroembolic kidney disease. Renal Fellow Network Web site. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.renalfellow.org/2020/02/14/kidney-biopsy-of-the-month-atheroembolic-kidney-disease/">https://www.renalfellow.org/2020/02/14/kidney-biopsy-of-the-month-atheroembolic-kidney-disease/</ext-link>. Published February 14, 2020. Accessed June 16, 2024.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Cholesterol__emboli__in__the__glomerulus__histology__HandE" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-17941.s18">
        <fig id="article-17941.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Cholesterol Emboli in the Glomerulus, Histology, PAS. Large atheroembolus occluding the renal artery (black arrow) and a glomerulus showing a cholesterol cleft (white arrowhead), Periodic acid-Schiff. Seker P. Kidney biopsy of the month: atheroembolic kidney disease. Renal Fellow Network Web site.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.renalfellow.org/2020/02/14/kidney-biopsy-of-the-month-atheroembolic-kidney-disease/."> https://www.renalfellow.org/2020/02/14/kidney-biopsy-of-the-month-atheroembolic-kidney-disease/.</ext-link> Published February 14, 2020. Accessed June 16, 2024.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Cholesterol__emboli__in__the__glomerulus__histology__PAS" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-17941.s19">
        <title>References</title>
        <ref id="article-17941.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carvajal</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Grismer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Berman</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Atheroembolism. An etiologic factor in renal insufficiency, gastrointestinal hemorrhages, and peripheral vascular diseases.</article-title>
            <source>Arch Intern Med</source>
            <year>1967</year>
            <month>Jun</month>
            <volume>119</volume>
            <issue>6</issue>
            <fpage>593</fpage>
            <page-range>593-9</page-range>
            <pub-id pub-id-type="pmid">5298059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Darsee</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Cholesterol embolism: the great masquerader.</article-title>
            <source>South Med J</source>
            <year>1979</year>
            <month>Feb</month>
            <volume>72</volume>
            <issue>2</issue>
            <fpage>174</fpage>
            <page-range>174-80</page-range>
            <pub-id pub-id-type="pmid">371003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cappiello</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Espinoza</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Adelman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aguilar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vasey</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Germain</surname>
                <given-names>BF</given-names>
              </name>
            </person-group>
            <article-title>Cholesterol embolism: a pseudovasculitic syndrome.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>1989</year>
            <month>May</month>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>240</fpage>
            <page-range>240-6</page-range>
            <pub-id pub-id-type="pmid">2727705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x00218;tefan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zugravu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stancu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gherghiceanu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Terinte-Balcan</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Atheroembolic kidney disease: The under-recognized silent killer.</article-title>
            <source>Clin Case Rep</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>1824</fpage>
            <page-range>1824-1825</page-range>
            <pub-id pub-id-type="pmid">33768956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chaudhary</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kashani</surname>
                <given-names>KB</given-names>
              </name>
            </person-group>
            <article-title>Acute Kidney Injury Management Strategies Peri-Cardiovascular Interventions.</article-title>
            <source>Interv Cardiol Clin</source>
            <year>2023</year>
            <month>Oct</month>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>555</fpage>
            <page-range>555-572</page-range>
            <pub-id pub-id-type="pmid">37673499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Bayliss</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zhuang</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cholesterol Crystal Embolism and Chronic Kidney Disease.</article-title>
            <source>Int J Mol Sci</source>
            <year>2017</year>
            <month>May</month>
            <day>24</day>
            <volume>18</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">28538699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vassalotti</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Delgado</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Whelton</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Atheroembolic Renal Disease.</article-title>
            <source>Am J Ther</source>
            <year>1996</year>
            <month>Jul</month>
            <volume>3</volume>
            <issue>7</issue>
            <fpage>544</fpage>
            <page-range>544-549</page-range>
            <pub-id pub-id-type="pmid">11862288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scolari</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ravani</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Atheroembolic renal disease.</article-title>
            <source>Lancet</source>
            <year>2010</year>
            <month>May</month>
            <day>08</day>
            <volume>375</volume>
            <issue>9726</issue>
            <fpage>1650</fpage>
            <page-range>1650-60</page-range>
            <pub-id pub-id-type="pmid">20381857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mittal</surname>
                <given-names>BV</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Rennke</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Atheroembolic renal disease: a silent masquerader.</article-title>
            <source>Kidney Int</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>73</volume>
            <issue>1</issue>
            <fpage>126</fpage>
            <page-range>126-30</page-range>
            <pub-id pub-id-type="pmid">17667989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kronzon</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Saric</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cholesterol embolization syndrome.</article-title>
            <source>Circulation</source>
            <year>2010</year>
            <month>Aug</month>
            <day>10</day>
            <volume>122</volume>
            <issue>6</issue>
            <fpage>631</fpage>
            <page-range>631-41</page-range>
            <pub-id pub-id-type="pmid">20697039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fukumoto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tsutsui</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tsuchihashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Masumoto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Takeshita</surname>
                <given-names>A</given-names>
              </name>
              <collab>Cholesterol Embolism Study(CHEST) Investigators</collab>
            </person-group>
            <article-title>The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2003</year>
            <month>Jul</month>
            <day>16</day>
            <volume>42</volume>
            <issue>2</issue>
            <fpage>211</fpage>
            <page-range>211-6</page-range>
            <pub-id pub-id-type="pmid">12875753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Modi</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>VK</given-names>
              </name>
            </person-group>
            <article-title>Atheroembolic renal disease.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>12</volume>
            <issue>8</issue>
            <fpage>1781</fpage>
            <page-range>1781-1787</page-range>
            <pub-id pub-id-type="pmid">11461954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scott</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ethier</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hawley</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pascoe</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Viecelli</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Burden of kidney failure from atheroembolic disease and association with survival in people receiving dialysis in Australia and New Zealand: a multi-centre registry study.</article-title>
            <source>BMC Nephrol</source>
            <year>2021</year>
            <month>Dec</month>
            <day>02</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>401</fpage>
            <pub-id pub-id-type="pmid">34856938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pirson</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Honhon</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cosyns</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>van Ypersele</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Cholesterol embolism in a renal graft after treatment with streptokinase.</article-title>
            <source>Br Med J (Clin Res Ed)</source>
            <year>1988</year>
            <month>Feb</month>
            <day>06</day>
            <volume>296</volume>
            <issue>6619</issue>
            <fpage>394</fpage>
            <page-range>394-5</page-range>
            <pub-id pub-id-type="pmid">3125916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Killen</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Leichtman</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Cholesterol emboli presenting as acute allograft dysfunction after renal transplantation.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>1995</year>
            <month>Aug</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>165</fpage>
            <page-range>165-70</page-range>
            <pub-id pub-id-type="pmid">7579080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ripple</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Charney</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nadasdy</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Cholesterol embolization in renal allografts.</article-title>
            <source>Transplantation</source>
            <year>2000</year>
            <month>May</month>
            <day>27</day>
            <volume>69</volume>
            <issue>10</issue>
            <fpage>2221</fpage>
            <page-range>2221-5</page-range>
            <pub-id pub-id-type="pmid">10852632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rudnick</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Berns</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Goldfarb</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Nephrotoxic risks of renal angiography: contrast media-associated nephrotoxicity and atheroembolism--a critical review.</article-title>
            <source>Am J Kidney Dis</source>
            <year>1994</year>
            <month>Oct</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>713</fpage>
            <page-range>713-27</page-range>
            <pub-id pub-id-type="pmid">7942832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamamoto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sakai</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kaikoi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yomogida</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kajikawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wada</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yuasa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ogura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Miyagawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kitajima</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Toyama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hara</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wada</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Iwata</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Cholesterol Crystal Embolism: Autopsy-proven Gastrointestinal Lesions, Pancreatitis, and End-stage Kidney Disease Which Developed after Undergoing Selective Abdominal Angiography.</article-title>
            <source>Intern Med</source>
            <year>2024</year>
            <month>May</month>
            <day>09</day>
            <pub-id pub-id-type="pmid">38719599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scolari</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ravani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gaggi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Santostefano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rollino</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stabellini</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Colla</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Viola</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Maiorca</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Venturelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bonardelli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Faggiano</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>The challenge of diagnosing atheroembolic renal disease: clinical features and prognostic factors.</article-title>
            <source>Circulation</source>
            <year>2007</year>
            <month>Jul</month>
            <day>17</day>
            <volume>116</volume>
            <issue>3</issue>
            <fpage>298</fpage>
            <page-range>298-304</page-range>
            <pub-id pub-id-type="pmid">17606842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scolari</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tardanico</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pola</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Viola</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Movilli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Maiorca</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Cholesterol crystal embolism: A recognizable cause of renal disease.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>1089</fpage>
            <page-range>1089-109</page-range>
            <pub-id pub-id-type="pmid">11096032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Polu</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical problem-solving. Needle in a haystack.</article-title>
            <source>N Engl J Med</source>
            <year>2006</year>
            <month>Jan</month>
            <day>05</day>
            <volume>354</volume>
            <issue>1</issue>
            <fpage>68</fpage>
            <page-range>68-73</page-range>
            <pub-id pub-id-type="pmid">16394304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Piranavan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rajan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jindal</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A rare presentation of spontaneous atheroembolic renal disease: A case report.</article-title>
            <source>World J Nephrol</source>
            <year>2019</year>
            <month>Jun</month>
            <day>28</day>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>67</fpage>
            <page-range>67-74</page-range>
            <pub-id pub-id-type="pmid">31363463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mulay</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Anders</surname>
                <given-names>H-J</given-names>
              </name>
            </person-group>
            <article-title>Crystallopathies.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Sep</month>
            <day>29</day>
            <volume>375</volume>
            <issue>13</issue>
            <fpage>e29</fpage>
            <pub-id pub-id-type="pmid">27682056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martinon</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>P&#x000e9;trilli</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mayor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tardivel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tschopp</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Gout-associated uric acid crystals activate the NALP3 inflammasome.</article-title>
            <source>Nature</source>
            <year>2006</year>
            <month>Mar</month>
            <day>09</day>
            <volume>440</volume>
            <issue>7081</issue>
            <fpage>237</fpage>
            <page-range>237-41</page-range>
            <pub-id pub-id-type="pmid">16407889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duewell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kono</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rayner</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Sirois</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Vladimer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bauernfeind</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Abela</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Franchi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nu&#x000f1;ez</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schnurr</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Espevik</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lien</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Rock</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Hornung</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Latz</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals.</article-title>
            <source>Nature</source>
            <year>2010</year>
            <month>Apr</month>
            <day>29</day>
            <volume>464</volume>
            <issue>7293</issue>
            <fpage>1357</fpage>
            <page-range>1357-61</page-range>
            <pub-id pub-id-type="pmid">20428172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Corr</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Dunne</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cholesterol crystals activate Syk and PI3 kinase in human macrophages and dendritic cells.</article-title>
            <source>Atherosclerosis</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>251</volume>
            <fpage>197</fpage>
            <page-range>197-205</page-range>
            <pub-id pub-id-type="pmid">27356299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kiyotake</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Oh-Hora</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ishikawa</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Miyamoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ishibashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yamasaki</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Human Mincle Binds to Cholesterol Crystals and Triggers Innate Immune Responses.</article-title>
            <source>J Biol Chem</source>
            <year>2015</year>
            <month>Oct</month>
            <day>16</day>
            <volume>290</volume>
            <issue>42</issue>
            <fpage>25322</fpage>
            <page-range>25322-32</page-range>
            <pub-id pub-id-type="pmid">26296894</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Samstad</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Niyonzima</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nymo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aune</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bakke</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Lappeg&#x000e5;rd</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Brekke</surname>
                <given-names>OL</given-names>
              </name>
              <name>
                <surname>Lambris</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Dam&#x000e5;s</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Latz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mollnes</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Espevik</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release.</article-title>
            <source>J Immunol</source>
            <year>2014</year>
            <month>Mar</month>
            <day>15</day>
            <volume>192</volume>
            <issue>6</issue>
            <fpage>2837</fpage>
            <page-range>2837-45</page-range>
            <pub-id pub-id-type="pmid">24554772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Niyonzima</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Samstad</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Aune</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bakke</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Rokstad</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Dam&#x000e5;s</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Mollnes</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Latz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Espevik</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Reconstituted High-Density Lipoprotein Attenuates Cholesterol Crystal-Induced Inflammatory Responses by Reducing Complement Activation.</article-title>
            <source>J Immunol</source>
            <year>2015</year>
            <month>Jul</month>
            <day>01</day>
            <volume>195</volume>
            <issue>1</issue>
            <fpage>257</fpage>
            <page-range>257-64</page-range>
            <pub-id pub-id-type="pmid">26026058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nymo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Niyonzima</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Espevik</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mollnes</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>Cholesterol crystal-induced endothelial cell activation is complement-dependent and mediated by TNF.</article-title>
            <source>Immunobiology</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>219</volume>
            <issue>10</issue>
            <fpage>786</fpage>
            <page-range>786-92</page-range>
            <pub-id pub-id-type="pmid">25053140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scoble</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>O'Donnell</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Renal atheroembolic disease: the Cinderella of nephrology?</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>1996</year>
            <month>Aug</month>
            <volume>11</volume>
            <issue>8</issue>
            <fpage>1516</fpage>
            <page-range>1516-7</page-range>
            <pub-id pub-id-type="pmid">8856200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nasri</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mubarak</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Contrast induced nephropathy has to be differentiated from kidney injury due to atheroembolic disease.</article-title>
            <source>J Renal Inj Prev</source>
            <year>2013</year>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>107</fpage>
            <page-range>107-8</page-range>
            <pub-id pub-id-type="pmid">25340143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sakan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nakatani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Asai</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Matsui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iwano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>[Case of purpura nephritis accompanied by idiopathic cholesterol embolism].</article-title>
            <source>Nihon Jinzo Gakkai Shi</source>
            <year>2012</year>
            <volume>54</volume>
            <issue>5</issue>
            <fpage>622</fpage>
            <page-range>622-8</page-range>
            <pub-id pub-id-type="pmid">22991843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chu</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Folkert</surname>
                <given-names>VW</given-names>
              </name>
            </person-group>
            <article-title>Renal function recovery in chronic dialysis patients.</article-title>
            <source>Semin Dial</source>
            <year>2010</year>
            <season>Nov-Dec</season>
            <volume>23</volume>
            <issue>6</issue>
            <fpage>606</fpage>
            <page-range>606-13</page-range>
            <pub-id pub-id-type="pmid">21166875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Steiger</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gudermann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mammadova-Bach</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Anders</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Both hyperglycemia and hyperuricemia aggravate acute kidney injury during cholesterol embolism syndrome despite opposite effects on kidney infarct size.</article-title>
            <source>Kidney Int</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>104</volume>
            <issue>1</issue>
            <fpage>139</fpage>
            <page-range>139-150</page-range>
            <pub-id pub-id-type="pmid">37001603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Desai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ram</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Prayaga</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dakshinamurty</surname>
                <given-names>KV</given-names>
              </name>
            </person-group>
            <article-title>Cholesterol crystal embolization (CCE): Improvement of renal function with high-dose corticosteroid treatment.</article-title>
            <source>Saudi J Kidney Dis Transpl</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>327</fpage>
            <page-range>327-30</page-range>
            <pub-id pub-id-type="pmid">21422636</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kronzon</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tunick</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Aortic atherosclerotic disease and stroke.</article-title>
            <source>Circulation</source>
            <year>2006</year>
            <month>Jul</month>
            <day>04</day>
            <volume>114</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <page-range>63-75</page-range>
            <pub-id pub-id-type="pmid">16818829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abela</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Vedre</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Janoudi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Durga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tamhane</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization.</article-title>
            <source>Am J Cardiol</source>
            <year>2011</year>
            <month>Jun</month>
            <day>15</day>
            <volume>107</volume>
            <issue>12</issue>
            <fpage>1710</fpage>
            <page-range>1710-7</page-range>
            <pub-id pub-id-type="pmid">21507364</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Th&#x000e9;riault</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Agharazzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dumont</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pichette</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ouimet</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Leblanc</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Atheroembolic renal failure requiring dialysis: potential for renal recovery? A review of 43 cases.</article-title>
            <source>Nephron Clin Pract</source>
            <year>2003</year>
            <volume>94</volume>
            <issue>1</issue>
            <fpage>c11</fpage>
            <page-range>c11-8</page-range>
            <pub-id pub-id-type="pmid">12806187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scolari</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ravani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pola</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guerini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zubani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Movilli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Savoldi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Malberti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Maiorca</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Predictors of renal and patient outcomes in atheroembolic renal disease: a prospective study.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>1584</fpage>
            <page-range>1584-90</page-range>
            <pub-id pub-id-type="pmid">12761259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Faria</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vidinha</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>P&#x000ea;go</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Garrido</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lemos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lima</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sorbo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gomes</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Carvalho</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Loureiro</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sousa</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Atheroembolic renal disease with rapid progression and fatal outcome.</article-title>
            <source>Clin Exp Nephrol</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>159</fpage>
            <page-range>159-63</page-range>
            <pub-id pub-id-type="pmid">21069411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17941.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frank</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>[Cholesterol embolism syndrome: a rare, but severe complication in patients with atherosclerosis].</article-title>
            <source>Dtsch Med Wochenschr</source>
            <year>2012</year>
            <month>May</month>
            <volume>137</volume>
            <issue>21</issue>
            <fpage>1130</fpage>
            <page-range>1130-4</page-range>
            <pub-id pub-id-type="pmid">22588660</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
